Tuberculosis: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• TNF 0
• IL-1 0
• IL-6 0
• IL-17 0
• STING 0
• NLRP3 0
• STAT3 0
• HMGB1 0
• JAK 0
• PD-1 0
• PI3K 0
• TLR4 0
• TP53 0
• TYK2 0
• AKT 0
• CTLA-4 0
• IL-23 0
• mTOR 0
• NRF2 0
• PPAR 0
• SIRT1 0
• CCR5 0
• CD40 0
• EGFR 0
• MAPK 0
• PD-L1 0
• ABL1 0
• AMPK 0
• CD20 0
• COX-2 0
• GPX4 0
• JNK 0
• TFEB 0
• TREM2 0
• VEGF 0
• YAP 0
• ALK 0
• ATM 0
• AXL 0
• BCL-2 0
• BRAF 0
• CD38 0
• FTO 0
• HDAC 0
• HIF-1 0
• HSP90 0
• IL-15 0
• IL-4 0
• MMP-9 0
• NOTCH3 0
• NTRK 0
• PDE4 0
• PKM2 0
• PRMT5 0
• PTEN 0
• STK11 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Human JAK2 genotypes underlying tuberculosis (JAK2-TB)

  Imagine Institut des Maladies Genetiques Necker Enfants Malades Fondation· Paris, France· EU contribution €242,261· until May 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-Cofund-CE

  Empowering the Next Generation of Researchers for Advancing Global Antimicrobial Resistance Endeavors (ENGAGE)

  Valsts zinatniskais instituts ""Nacionalais petniecibas un inovaciju instituts""""· Riga, Latvia· EU contribution €1,206,000· until Dec 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Point-of-care Lab-on-Chip Detection of Host Response in Febrile Illness for Diagnosis and Etiology Research (PATHFINDER)

  Imperial College of Science Technology and Medicine· London, United Kingdom· EU contribution €2,753,896· until Mar 2030· 4 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Deciphering the molecular architecture and infection mechanisms of corynephages within native host environments (ISPHAGE)

  Universite de Lausanne· Lausanne, Switzerland· EU contribution €292,119· until Sept 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  An equity microsimulation approach to forecast the impact of social protection on diseases of poverty in low- and middle-income countries: the case of tuberculosis (SIMPACT-TB)

  Fundacion Privada Instituto de Salud Global Barcelona· Barcelona, Spain· EU contribution €209,915· until Aug 2028

5 of 62 running projects, newest first. Listed amounts together: €453.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 33
• Organoids 5
• Mendelian Randomization Analysis 7
• CRISPR-Cas Systems 25
• Gene Expression Profiling 103
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 136
• Exome Sequencing 5
• Proteomics 47
• Metabolomics 39
• Mass Spectrometry 16
• Flow Cytometry 16
• Immunohistochemistry 9
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 85
• Machine Learning 102
• Deep Learning 41
• Cohort Studies 103
• Genome-Wide Association Study 12

• Utilization of the CRISPR-Cas system for investigating tuberculosis drug resistance.

  Mol Biol Rep, Oct 2026

• Aptamer-CRISPR/Cas as a tool in point-of-care testing of infectious diseases.

  Talanta, Oct 2026

• Unified hybrid RNA-regulated CRISPR diagnostic for concurrent Mycobacterium tuberculosis detection and rifampicin resistance profiling.

  Biosens Bioelectron, Oct 2026

• Programmable thermoregulation of the nuclease activity of LbCas12a.

  Biosens Bioelectron, Oct 2026

• An XNA-CRISPR Platform for PAM-Free Detection of the katG Ser315Thr Mutation Associated with Isoniazid Resistance in Tuberculosis.

  Anal Chem, Sept 2026

• A rapid CRISPR-based nanodroplet assay enables direct clinical identification of mycobacteria species.

  Sci Transl Med, Sept 2026

• Multiplex crRNAs powered CRISPRCas13a detection for rifampicin-resistant mycobacterium tuberculosis.

  J Infect Public Health, Aug 2026

• Recent Advances in CRISPR/Cas Systems for Respiratory Pathogen Diagnostics.

  Viruses, Aug 2026

• Amplification-free electrochemiluminescence biosensors based on peptide-templated gold nanocluster and CRISPR-Cas12a for Mycobacterium tuberculosis IS6110 detection.

  Anal Chim Acta, Aug 2026

• Engineered CRISPR-Cas systems for transcriptional regulation and precision molecular diagnostics: advances, challenges, and emerging microfluidic integration.

  Clin Chim Acta, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.